


# Obesity Prevalence Appears to Be Leveling Off

BY SHARON WORCESTER

FROM JAMA

**T**he prevalence of obesity in the United States appears to have plateaued, according to data from the 2009-2010 National Health and Nutrition Examination Survey (NHANES) conducted by the U.S. Centers for Disease Control and Prevention.

Following dramatic increases in the prevalence of obesity in adults, children, and adolescents in the 1980s and 1990s, as well as changes in the distribution of body mass index, no significant changes were seen in 2009-2010, compared with 2003-2008 figures in adults, and compared with 2007-2008 prevalence rates in children and adolescents.



**Obesity prevalence plateaued overall, but continued to climb in men.**

For example, based on data from the 5,926 men and women with measured weight and height who participated in the 2009-2010 NHANES, the age-adjusted prevalence of obesity was roughly 35% for both men and women, which was not significantly different overall compared with the prevalence from 2003-2008, Katherine M. Flegal, Ph.D., and her colleagues from the National Center for Health Statistics, CDC, Hyattsville, Md., reported.

Despite the lack of change overall, the analysis of adult data did indicate, however, that obesity increased in certain segments of the population. While no significant increase was seen among women overall (age- and race-adjusted annual change in odds ratio from 1999 to 2010, 1.01), statistically significant increases were seen among non-Hispanic black women (OR, 1.03) and Mexican American women (1.03), the investigators noted (JAMA 2012 Jan. 17 [doi:10.1001/jama.2012.39]).

A significant linear trend was also seen in men over the 12-year period (annual change in OR, 1.04).

As for BMI, the age-adjusted mean in both men and women was 28.7, and the trends over time in this study were similar to those seen with obesity, with a significant increase seen in men, but not in

women, over the 12 years, the investigators said.

In a separate cross-sectional analysis of data from 4,111 children and adolescents who participated in NHANES, the 2009-2010 obesity prevalence of 9.7% in infants and toddlers up to age 2 years, and 16.9% for those aged 2-19 years, did not differ significantly from the 2007-2008 prevalence, and no difference was seen between males and females in regard to

obesity prevalence, Cynthia L. Ogden, Ph.D., and her colleagues, also from the National Center for Health Statistics, CDC, reported in the same issue of JAMA.

A trend analysis over the 12-year study period did indicate, however, that the obesity prevalence among males aged 2-19 years increased significantly between 1999-2000 and 2009-2010 (OR, 1.05) per 2-year survey cycle, and that there was a

significant increasing trend for non-Hispanic black males (OR, 1.10). Also, BMI increased significantly in males aged 12 through 19 years (JAMA 2012 Jan. 17 [doi:10.1001/jama.2012.40]).

Investigators for both analyses noted that it is important to keep in mind that BMI is an "imperfect measure of body fat."

None of the authors indicated having relevant conflicts of interest. ■

**NEW LOW-DOSE**

# Androderm® 2mg/4 mg

**Smaller Dose, Reliable Results**



- **SMALLER PATCH WITH 20% LESS ACTIVE INGREDIENT<sup>1,2\*</sup>**
- **RELIABLE EFFICACY YOU EXPECT<sup>1</sup>**
- **STRONG SAFETY PROFILE<sup>1,2</sup>**

\*Compared to Androderm® 2.5 mg/5 mg

## ANDRODERM®

(testosterone transdermal system)

References: 1. Androderm® full Prescribing Information, Watson Pharma, Inc. October 2011. 2. Data on file, Watson Laboratories, Inc.

Androderm® is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

**IMPORTANT SAFETY INFORMATION**

Androderm® should not be used in men with carcinoma of the breast, known or suspected carcinoma of the prostate, or patients with pre-existing cardiac, renal, or hepatic disease. Androderm® should also not be used in pregnant or breastfeeding women, as testosterone may cause fetal harm. Patients with benign prostatic hyperplasia (BPH) should be monitored for worsening signs and symptoms, and exposure of Androderm® to women or children should be avoided. Exogenous administration of testosterone may lead to azoospermia, and sleep apnea may occur in those with risk factors. Patients should be monitored for prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit, and hemoglobin. In a clinical study of 36 patients treated with Androderm®, skin irritation from the patch was the most common adverse event (pruritus at application site [17%]), followed by application site vesicles (6%), and back pain (6%).

Please see brief summary of full Prescribing Information on the following page.


© 2011, Watson Pharma, Inc., Parsippany, NJ 07054. All rights reserved. 07745 10/11

For more information  
visit [Androderm.com](http://Androderm.com)